Ceribell

Company profile

About Ceribell

Ceribell is a medical technology company specializing in point-of-care electroencephalography (EEG) systems powered by artificial intelligence. The company's flagship product combines a wearable EEG device with Clarity, an FDA-cleared machine learning algorithm that continuously monitors brain activity and detects seizures and status epilepticus in real-time. Designed for rapid deployment in critical care settings, the Ceribell system can be set up within minutes with minimal training, providing continuous monitoring and instant bedside alerts for suspected seizure activity. The Clarity AI algorithm analyzes EEG waveforms every 10 seconds, displaying seizure burden estimates and enabling clinicians to make timely treatment decisions. The system streams data to a secure, cloud-based portal with FedRAMP High cybersecurity authorization, allowing neurologists to remotely review EEG recordings from anywhere. Ceribell serves intensive care units, emergency departments, neurology departments, pediatric ICUs, and neonatal ICUs across health systems. The technology is validated across the largest age range ever addressed by seizure detection technology—from preterm neonates (25 weeks+) through adults. Clinical studies demonstrate the system's impact on reducing ICU length of stay, preventing unnecessary patient transfers, and improving patient outcomes. With over 45 peer-reviewed publications supporting its clinical evidence, Ceribell has achieved both FDA Breakthrough Device Designation and CMS New Technology Add-on Payment (NTAP) status. The company is publicly traded and continues to expand its capabilities with innovative features shaped by neurologist feedback to streamline workflows and deliver faster, more accurate neurological care.

Company description · Ceribell official website